Table 8

Summary of clinical outcomes and immune responses.

Patient Disease Sitesa Clinical Responseb Immune Responsec (Melan-A) Immune Responsec (Flu) Survival (days)
1 skin, lung CR Od Oe, D 750+
2 lung, s.c. PD     490
3 liver, lung, paraspinal, pelvis PD     162
4 lung, liver, LN, local NE/PD     17
5 s.c., liver SD     411
6 in-transit MR   C 750+
7 liver PD   C 300
8 lung, LN PD     335
9 lung, liver, skin, spleen PD   D 342
10 lung, liver PD C   539
11 liver, bone, lung NE/PD     26
12 liver NE     605
13 LN, lung, liver SD   D 266
14 LN, bone, liver PR   C, D 750+
15 s.c., lung, liver MR D C 750+
16 lung, LN MR   C 415
17 LN, skin PD     750+
18 LN SD C   465
19 lung, liver PD     416+
20 lung, liver, LN SD     117
21 soft tissue, LN, pleura SD   D 241
22 LN SD   C 439
23 lung, spleen, adrenal PD   C 285
24 LN, lung, spleen PD C C 638
25 lung, bone, pleura PD     81
26 LN PD     750+
27 skin, LN PD D   60+
28 s.c., skin, LN, lung PD     60

aDisease sites: LN, lymph node. bClinical outcome: CR, complete response; PR, partial response; MR, mixed response; PD, progressive disease; SD, stable disease; NE, not evaluable. cImmune responses: D, DTH; C, CTL; O, other. dNegative in split-well assay; positive ELIspot assay. eNegative in split-well assay; positive response in bulk culture cytotoxicity assay.